Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer.
Sign Up to like & getrecommendations! Published in 2020 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2020.104474
Abstract: Human epidermal growth factor receptor 2 (HER2) overexpression, as a predictive biomarker, is associated with more tumor aggressiveness and worse clinical outcomes in cancer, whereas it's accurate identification has led to the choice of effective… read more here.
Keywords: dota ser; peptide based; her2 overexpression; her2 ... See more keywords
Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.334
Abstract: e16059Background: Trastuzumab combined with chemotherapy is the standard first-line regimen in HER2- overexpression advanced gastric cancer, and there is no established therapy in the second-line s... read more here.
Keywords: pharmacokinetics efficacy; overexpression advanced; safety pharmacokinetics; her2 overexpression ... See more keywords
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0267027
Abstract: ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them… read more here.
Keywords: her3 mutations; her3; her2 overexpression; activity ... See more keywords
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18992
Abstract: Antagonizing the oncogenic effects of human epidermal growth factor receptor 2 (HER2) with current anti-HER2 agents has not yet yielded major progress in the treatment of advanced HER2-positive epithelial ovarian cancer (EOC). Using preclinical models… read more here.
Keywords: growth; her2 overexpression; cancer; her2 ... See more keywords